FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1519231732> ?p ?o ?g. }

• W1519231732 abstract "Background Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy whose incidence is expected to increase in the United Kingdom, Western Europe, and Australia over the next 20 years as a result of occupational exposure to asbestos fibres. Surgery is feasible in only a small proportion of cases, and radiotherapy and cytotoxic chemotherapy are used in palliation. Pemetrexed is the first and only chemotherapy agent that has been granted a marketing approval for use in combination with cisplatin for the treatment of chemo‐naïve patients with unresectable MPM. Objectives To examine evidence on the clinical effectiveness of pemetrexed disodium used in combination with cisplatin for the treatment of unresectable malignant pleural mesothelioma in chemotherapy naïve patients compared with other cytotoxic agents used alone or in combination, or supportive care. Search methods CENTRAL (Issue 2, 2005), EMBASE (1980‐2005), MEDLINE (1980‐2005), HTA database (1990‐2005), Web of Knowledge (1990‐2005) and handsearching (including reference lists of retrieved articles and the pharmaceutical company submission to to NICE), up to October 2005. Selection criteria Randomised Controlled Trials (RCTs) where the use of pemetrexed disodium in combination with cisplatin is compared with other cytotoxic agents, or supportive care for the treatment of malignant pleural mesothelioma (or non‐RCTs, in the absence of RCT data ). Data collection and analysis Outcomes included overall survival, tumour response, progression‐free survival, toxicity and quality of life. Data extraction and quality assessment of included trials was completed independently. Trial data and quality assessment were tabulated and presented narratively. Main results One RCT involving 448 patients and comparing pemetrexed plus cisplatin versus cisplatin alone for the treatment of unresectable malignant mesothelioma was included in the review. In the intention‐to‐treat study population, the median survival was statistically significantly longer in the combination arm of pemetrexed plus cisplatin when compared with the cisplatin alone arm. (12.1 and 9.3 months, respectively, p=0.002). The incidence of grade 3/4 toxicities was higher in the combination arm compared with the cisplatin alone arm. Authors' conclusions Pemetrexed disodium in combination with cisplatin and with folic acid and vitamin B12 supplementation may improve survival when used in combination with cisplatin in good performance status patients. Further studies including patients with poor performance status are needed in order to generalise the treatment findings. Further studies are also needed into the optimum chemotherapy, and a clear definition of what constitutes best supportive care." @default.
• W1519231732 created "2016-06-24" @default.
• W1519231732 creator A5043140431 @default.
• W1519231732 creator A5066990182 @default.
• W1519231732 creator A5068763092 @default.
• W1519231732 creator A5072733614 @default.
• W1519231732 creator A5079590143 @default.
• W1519231732 date "2007-01-24" @default.
• W1519231732 modified "2023-10-14" @default.
• W1519231732 title "Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma" @default.
• W1519231732 cites W170240083 @default.
• W1519231732 cites W1766286185 @default.
• W1519231732 cites W1869777220 @default.
• W1519231732 cites W1936937687 @default.
• W1519231732 cites W1960348144 @default.
• W1519231732 cites W1968154700 @default.
• W1519231732 cites W1989131755 @default.
• W1519231732 cites W1991881693 @default.
• W1519231732 cites W2018034853 @default.
• W1519231732 cites W2021208962 @default.
• W1519231732 cites W2062011274 @default.
• W1519231732 cites W2068178793 @default.
• W1519231732 cites W2077248800 @default.
• W1519231732 cites W2101834873 @default.
• W1519231732 cites W2102627969 @default.
• W1519231732 cites W2103421431 @default.
• W1519231732 cites W2106879636 @default.
• W1519231732 cites W2115237013 @default.
• W1519231732 cites W2127235139 @default.
• W1519231732 cites W2131149579 @default.
• W1519231732 cites W2147595306 @default.
• W1519231732 cites W2156145816 @default.
• W1519231732 cites W2168841084 @default.
• W1519231732 cites W2169833424 @default.
• W1519231732 cites W2223091784 @default.
• W1519231732 cites W2241228657 @default.
• W1519231732 cites W2273112624 @default.
• W1519231732 cites W2327645250 @default.
• W1519231732 cites W4211134618 @default.
• W1519231732 doi "https://doi.org/10.1002/14651858.cd005574.pub2" @default.
• W1519231732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17253564" @default.
• W1519231732 hasPublicationYear "2007" @default.
• W1519231732 type Work @default.
• W1519231732 sameAs 1519231732 @default.
• W1519231732 citedByCount "13" @default.
• W1519231732 countsByYear W15192317322013 @default.
• W1519231732 countsByYear W15192317322014 @default.
• W1519231732 countsByYear W15192317322019 @default.
• W1519231732 countsByYear W15192317322021 @default.
• W1519231732 countsByYear W15192317322022 @default.
• W1519231732 crossrefType "journal-article" @default.
• W1519231732 hasAuthorship W1519231732A5043140431 @default.
• W1519231732 hasAuthorship W1519231732A5066990182 @default.
• W1519231732 hasAuthorship W1519231732A5068763092 @default.
• W1519231732 hasAuthorship W1519231732A5072733614 @default.
• W1519231732 hasAuthorship W1519231732A5079590143 @default.
• W1519231732 hasBestOaLocation W15192317322 @default.
• W1519231732 hasConcept C126322002 @default.
• W1519231732 hasConcept C141071460 @default.
• W1519231732 hasConcept C142724271 @default.
• W1519231732 hasConcept C143998085 @default.
• W1519231732 hasConcept C168563851 @default.
• W1519231732 hasConcept C2776694085 @default.
• W1519231732 hasConcept C2777240266 @default.
• W1519231732 hasConcept C2777407522 @default.
• W1519231732 hasConcept C2778239845 @default.
• W1519231732 hasConcept C535046627 @default.
• W1519231732 hasConcept C71924100 @default.
• W1519231732 hasConceptScore W1519231732C126322002 @default.
• W1519231732 hasConceptScore W1519231732C141071460 @default.
• W1519231732 hasConceptScore W1519231732C142724271 @default.
• W1519231732 hasConceptScore W1519231732C143998085 @default.
• W1519231732 hasConceptScore W1519231732C168563851 @default.
• W1519231732 hasConceptScore W1519231732C2776694085 @default.
• W1519231732 hasConceptScore W1519231732C2777240266 @default.
• W1519231732 hasConceptScore W1519231732C2777407522 @default.
• W1519231732 hasConceptScore W1519231732C2778239845 @default.
• W1519231732 hasConceptScore W1519231732C535046627 @default.
• W1519231732 hasConceptScore W1519231732C71924100 @default.
• W1519231732 hasIssue "4" @default.
• W1519231732 hasLocation W15192317321 @default.
• W1519231732 hasLocation W15192317322 @default.
• W1519231732 hasLocation W15192317323 @default.
• W1519231732 hasOpenAccess W1519231732 @default.
• W1519231732 hasPrimaryLocation W15192317321 @default.
• W1519231732 hasRelatedWork W1978520323 @default.
• W1519231732 hasRelatedWork W2083305999 @default.
• W1519231732 hasRelatedWork W2092151800 @default.
• W1519231732 hasRelatedWork W2162580433 @default.
• W1519231732 hasRelatedWork W2222520153 @default.
• W1519231732 hasRelatedWork W2413537020 @default.
• W1519231732 hasRelatedWork W2591408645 @default.
• W1519231732 hasRelatedWork W2953220268 @default.
• W1519231732 hasRelatedWork W2953636941 @default.
• W1519231732 hasRelatedWork W3205509964 @default.
• W1519231732 hasVolume "2012" @default.
• W1519231732 isParatext "false" @default.
• W1519231732 isRetracted "false" @default.
• W1519231732 magId "1519231732" @default.
• W1519231732 workType "article" @default.